News Image

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias

Read more at globenewswire.com

WINDTREE THERAPEUTICS INC

NASDAQ:WINT (2/11/2025, 8:00:01 PM)

After market: 0.22 +0.06 (+37.5%)

0.16

+0.02 (+13.15%)

WINT Latest News and Analysis

ChartMill News Image18 days ago - ChartmillFriday's after hours session: top gainers and losers

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Follow ChartMill for more